Epothilones in the treatment of ovarian cancer

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Bollag DM, McQueney PA, Zhu J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res.55,2325–2333 (1995).
  Medline CASGoogle Scholar
• 2  Fojo AT, Menefee M: Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin. Oncol.32,S3–S8 (2005).
  Medline CASGoogle Scholar
• 3  Sparano JA, Vrdoljak E, Rixe O et al.: Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol.28,3256–3263 (2010).▪▪ First randomized Phase III trial of ixabepilone in solid tumors.
  Medline CASGoogle Scholar
• 4  Wartmann M, Altmann KH: The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anticancer Agents2,123–148 (2002).
  Medline CASGoogle Scholar
• 5  Goodin S, Kane MP, Rubin EH: Epothilones: mechanism of action and biologic activity. J. Clin. Oncol.22,2015–2025 (2004).
  Medline CASGoogle Scholar
• 6  Martello LA, Verdier-Pinard P, Shen HJ et al.: Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res.63,1207–1213 (2003).
  Medline CASGoogle Scholar
• 7  Verrills NM, Flemming CL, Liu M et al.: Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem. Biol.10,597–607 (2003).
  Medline CASGoogle Scholar
• 8  Kamath K, Wilson L, Cabral F et al.: βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem.280,12902–12907 (2005).
  Medline CASGoogle Scholar
• 9  Stalder MW, Anthony CT, Woltering EA: Metronomic dosing enhances the anti-angiogenic effect of epothilone B. J. Surg. Res. DOI: 10.1016/j.jss.2009.12.001 (2009) (Epub ahead of print).
  MedlineGoogle Scholar
• 10  Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res.62,6938–6943 (2002).
  Medline CASGoogle Scholar
• 11  Woltering EA, Lewis JM, Maxwell PJ et al.: Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann. Surg.237,790–798; discussion 798–800 (2003).
  MedlineGoogle Scholar
• 12  Lee FY, Smykla R, Johnston K et al.: Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol.63,201–212 (2009).
  Medline CASGoogle Scholar
• 13  Michaud LB: The epothilones: how pharmacology relates to clinical utility. Ann. Pharmacother.43,1294–1309 (2009).
  Medline CASGoogle Scholar
• 14  Altmann KH, Wartmann M, O’Reilly T: Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta1470,M79–M91 (2000).
  Medline CASGoogle Scholar
• 15  Ferretti S, Allegrini PR, O’Reilly T et al.: Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin. Cancer Res.11,7773–7784 (2005).
  Medline CASGoogle Scholar
• 16  Willett CG, Boucher Y, di Tomaso E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10,145–147 (2004).
  Medline CASGoogle Scholar
• 17  Taghian AG, Abi-Raad R, Assaad SI et al.: Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol.23,1951–1961 (2005).
  Medline CASGoogle Scholar
• 18  Rubin EH, Rothermel J, Tesfaye F et al.: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol.23,9120–9129 (2005).
  Medline CASGoogle Scholar
• 19  Ten Bokkel Huinink WW, Sufliarsky J, Smit WM et al.: Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a Phase I, open-label, dose-escalation study. J. Clin. Oncol.27,3097–3103 (2009).
  Medline CASGoogle Scholar
• 20  Forster M, Kaye S, Oza A et al.: A Phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin. Cancer Res.13,4178–4184 (2007).
  Medline CASGoogle Scholar
• 21  Aghajanian C, Burris HA 3rd, Jones S et al.: Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol.25,1082–1088 (2007).
  Medline CASGoogle Scholar
• 22  Schelman W, Morgan-Meadows S, Bailey H et al.: A Phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother. Pharmacol.62,727–733 (2008).
  Medline CASGoogle Scholar
• 23  Hofstetter B, Vuong V, Broggini-Tenzer A et al.: Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin. Cancer Res.11,1588–1596 (2005).
  Medline CASGoogle Scholar
• 24  Fogh S, Machtay M, Werner-Wasik M et al.: Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys.77,1009–1016 (2010).
  Medline CASGoogle Scholar
• 25  Sridhar SS, Hotte SJ, Kollmannsberger CK et al.: Preventing patupilone-induced diarrhea with high-dose corticosteroids. J. Clin. Oncol.28, Abstract E13069 (2010).▪ Suggests that steroids could potentially reduce patupilone-induced diarrhea.
  Google Scholar
• 26  Roche H, Yelle L, Cognetti F et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol.25,3415–3420 (2007).
  Medline CASGoogle Scholar
• 27  Thomas E, Tabernero J, Fornier M et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol.25,3399–3406 (2007).
  Medline CASGoogle Scholar
• 28  De Geest K, Blessing JA, Morris RT et al.: Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J. Clin. Oncol.28,149–153 (2010).
  Medline CASGoogle Scholar
• 29  Smit WM, Sufliarsky J, Werner TL et al.: A Phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. J. Clin. Oncol.25, Abstract 5563 (2009).
  Google Scholar
• 30  Colombo N, Schwartz PE, Barnias A et al.: Results of a randomized, open-label, Phase III trial of patupilone versus pegylated liposomal doxorubicin in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian tube, or peritoneal cancer. Ann. Oncol.21,LBA24 (2010).▪▪ First randomized Phase III trial of patupilone in platinum-resistant ovarian cancer patients.
  Google Scholar
• 31  Ferrandina G, Ludovisi M, Lorusso D et al.: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol.26,890–896 (2008).
  Medline CASGoogle Scholar
• 32  Miller DS, Blessing JA, Krasner CN et al.: Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol.27,2686–2691 (2009).
  Medline CASGoogle Scholar
• 33  Gordon AN, Tonda M, Sun S et al.: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol.95,1–8 (2004).
  Medline CASGoogle Scholar
• 34  Egerton N: Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother. Pharmacol.66,1005–1012 (2010).
  Medline CASGoogle Scholar
• 35  Hussain A, DiPaola RS, Baron AD et al.: Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann. Oncol.20,492–497 (2009).
  Medline CASGoogle Scholar
• 36  Vansteenkiste J, Lara PN Jr, Le Chevalier T et al.: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J. Clin. Oncol.25,3448–3455 (2007).
  Medline CASGoogle Scholar
• 37  Hussain M, Tangen CM, Lara PN Jr et al.: Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol.23,8724–8729 (2005).
  MedlineGoogle Scholar
• 38  Rosenberg JE, Weinberg VK, Kelly WK et al.: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer110,556–563 (2007).
  Medline CASGoogle Scholar
• 39  Dizon DS, Blessing JA, McMeekin DS et al.: Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J. Clin. Oncol.27,3104–3108 (2009).
  Medline CASGoogle Scholar
• 40  Ozols RF, Bundy BN, Greer BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.21,3194–3200 (2003).
  Medline CASGoogle Scholar
• 41  Parmar MK, Ledermann JA, Colombo N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet361,2099–2106 (2003).
  Medline CASGoogle Scholar
• 42  Rose PG, Blessing JA, Ball HG et al.: A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.88,130–135 (2003).
  Medline CASGoogle Scholar
• 43  Markman M, Blessing J, Rubin SC et al.: Phase II trial of weekly paclitaxel (80 mg/m²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol.101,436–440 (2006).
  Medline CASGoogle Scholar
• 44  Baselga J, Zambetti M, Llombart-Cussac A et al.: Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol.27,526–534 (2009).
  Medline CASGoogle Scholar
• 45  Szakacs G, Paterson JK, Ludwig JA et al.: Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov.5,219–234 (2006).
  Medline CASGoogle Scholar
• 46  Pusztai L: Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann. Oncol.18(Suppl. 12),XII15–XII20 (2007).▪▪ Outlines potential predictive biomarkers of taxane therapy, which may also apply for other microtubule-stabilizing agents in other disease sites.
  MedlineGoogle Scholar
• 47  Tommasi S, Mangia A, Lacalamita R et al.: Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int. J. Cancer120,2078–2085 (2007).
  Medline CASGoogle Scholar
• 48  Rouzier R, Rajan R, Wagner P et al.: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA102,8315–8320 (2005).
  Medline CASGoogle Scholar